3.72 USD
-0.09 (-2.36%)
3.74 USD
+0.02 (+0.54%)
Taking everything into account, ESPR scores 2 out of 10 in our fundamental rating. ESPR was compared to 191 industry peers in the Pharmaceuticals industry. ESPR may be in some trouble as it scores bad on both profitability and health. ESPR is valied quite expensively at the moment, while it does show a decent growth rate.
1. Profitability
1.1 Basic Checks
In the past year ESPR has reported negative net income.
In the past year ESPR has reported a negative cash flow from operations.
ESPR had negative earnings in each of the past 5 years.
In the past 5 years ESPR always reported negative operating cash flow.
1.2 Ratios
ESPR's Return On Assets of -29.07% is in line compared to the rest of the industry. ESPR outperforms 53.40% of its industry peers.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| ROA | -29.07% | ||
| ROE | N/A | ||
| ROIC | N/A |
ROA(3y)-70.33%
ROA(5y)-64.43%
ROE(3y)N/A
ROE(5y)N/A
ROIC(3y)N/A
ROIC(5y)N/A
1.3 Margins
ESPR has a Gross Margin of 58.20%. This is in the better half of the industry: ESPR outperforms 69.11% of its industry peers.
ESPR's Gross Margin has been stable in the last couple of years.
ESPR does not have Profit Margin and Operating Margin available, so we won't be analyzing them here.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| OM | N/A | ||
| PM (TTM) | N/A | ||
| GM | 58.2% |
OM growth 3YN/A
OM growth 5YN/A
PM growth 3YN/A
PM growth 5YN/A
GM growth 3Y-1.04%
GM growth 5YN/A
2. Health
2.1 Basic Checks
ESPR does not have a ROIC to compare to the WACC, probably because it is not profitable.
ESPR has more shares outstanding than it did 1 year ago.
The number of shares outstanding for ESPR has been increased compared to 5 years ago.
ESPR has a better debt/assets ratio than last year.
2.2 Solvency
Based on the Altman-Z score of -5.26, we must say that ESPR is in the distress zone and has some risk of bankruptcy.
With a Altman-Z score value of -5.26, ESPR is not doing good in the industry: 64.92% of the companies in the same industry are doing better.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| Debt/Equity | N/A | ||
| Debt/FCF | N/A | ||
| Altman-Z | -5.26 |
ROIC/WACCN/A
WACC8.93%
2.3 Liquidity
A Current Ratio of 1.00 indicates that ESPR should not have too much problems paying its short term obligations.
ESPR has a Current ratio of 1.00. This is amonst the worse of the industry: ESPR underperforms 84.82% of its industry peers.
ESPR has a Quick Ratio of 1.00. This is a bad value and indicates that ESPR is not financially healthy enough and could expect problems in meeting its short term obligations.
The Quick ratio of ESPR (0.70) is worse than 85.86% of its industry peers.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| Current Ratio | 1 | ||
| Quick Ratio | 0.7 |
3. Growth
3.1 Past
The Earnings Per Share has grown by an impressive 21.87% over the past year.
ESPR shows a small growth in Revenue. In the last year, the Revenue has grown by 2.83%.
ESPR shows quite a strong growth in Revenue. Measured over the last years, the Revenue has been growing by 17.50% yearly.
EPS 1Y (TTM)21.87%
EPS 3YN/A
EPS 5YN/A
EPS Q2Q%-6.67%
Revenue 1Y (TTM)2.83%
Revenue growth 3Y61.84%
Revenue growth 5Y17.5%
Sales Q2Q%69.1%
3.2 Future
ESPR is expected to show a strong growth in Earnings Per Share. In the coming years, the EPS will grow by 65.47% yearly.
ESPR is expected to show a strong growth in Revenue. In the coming years, the Revenue will grow by 29.21% yearly.
EPS Next Y68.18%
EPS Next 2Y46.89%
EPS Next 3Y42.98%
EPS Next 5Y65.47%
Revenue Next Year26.51%
Revenue Next 2Y8.91%
Revenue Next 3Y9.52%
Revenue Next 5Y29.21%
3.3 Evolution
When comparing the Revenue growth rate of the last years to the growth rate of the upcoming years, we see that the growth is accelerating.
4. Valuation
4.1 Price/Earnings Ratio
The Price/Earnings Ratio is negative for ESPR. In the last year negative earnings were reported.
Based on the Price/Forward Earnings ratio of 94.41, the valuation of ESPR can be described as expensive.
ESPR's Price/Forward Earnings ratio is a bit cheaper when compared to the industry. ESPR is cheaper than 68.59% of the companies in the same industry.
ESPR's Price/Forward Earnings ratio indicates a rather expensive valuation when compared to the S&P500 average which is at 23.79.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| PE | N/A | ||
| Fwd PE | 94.41 |
4.2 Price Multiples
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| P/FCF | N/A | ||
| EV/EBITDA | N/A |
4.3 Compensation for Growth
ESPR's PEG Ratio(NY), which compensates the Price/Earnings for growth, indicates a correct valuation of the company.
ESPR's earnings are expected to grow with 42.98% in the coming years. This may justify a more expensive valuation.
PEG (NY)N/A
PEG (5Y)N/A
EPS Next 2Y46.89%
EPS Next 3Y42.98%
5. Dividend
5.1 Amount
ESPR does not give a dividend.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| Dividend Yield | 0% |
3.72
-0.09 (-2.36%)
Chartmill FA Rating
GICS SectorHealth Care
GICS IndustryGroupPharmaceuticals, Biotechnology & Life Sciences
GICS IndustryPharmaceuticals
Earnings (Last)
Earnings (Next)
Inst Owners46.36%
Inst Owner Change0%
Ins Owners0.49%
Ins Owner Change2.22%
Market Cap889.30M
Revenue(TTM)303.80M
Net Income(TTM)-105.83M
Analysts78.57
Price Target6.59 (77.15%)
Short Float %12.23%
Short Ratio4.77
Dividend
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| Dividend Yield | 0% |
Yearly DividendN/A
Dividend Growth(5Y)N/A
DPN/A
Div Incr Years0
Div Non Decr Years0
Ex-DateN/A
Surprises & Revisions
EPS beat(2)1
Avg EPS beat(2)-48.6%
Min EPS beat(2)-183.71%
Max EPS beat(2)86.52%
EPS beat(4)2
Avg EPS beat(4)-25.67%
Min EPS beat(4)-183.71%
Max EPS beat(4)86.52%
EPS beat(8)4
Avg EPS beat(8)56.17%
EPS beat(12)7
Avg EPS beat(12)40.36%
EPS beat(16)10
Avg EPS beat(16)32.71%
Revenue beat(2)2
Avg Revenue beat(2)19.06%
Min Revenue beat(2)10.02%
Max Revenue beat(2)28.11%
Revenue beat(4)4
Avg Revenue beat(4)16.35%
Min Revenue beat(4)10.02%
Max Revenue beat(4)28.11%
Revenue beat(8)7
Avg Revenue beat(8)23.5%
Revenue beat(12)10
Avg Revenue beat(12)16.66%
Revenue beat(16)12
Avg Revenue beat(16)13.5%
PT rev (1m)5.93%
PT rev (3m)6.23%
EPS NQ rev (1m)7.57%
EPS NQ rev (3m)6.64%
EPS NY rev (1m)0%
EPS NY rev (3m)0.85%
Revenue NQ rev (1m)2.71%
Revenue NQ rev (3m)14.11%
Revenue NY rev (1m)0.53%
Revenue NY rev (3m)11.55%
Valuation
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| PE | N/A | ||
| Fwd PE | 94.41 | ||
| P/S | 2.93 | ||
| P/FCF | N/A | ||
| P/OCF | N/A | ||
| P/B | N/A | ||
| P/tB | N/A | ||
| EV/EBITDA | N/A |
EPS(TTM)-0.5
EYN/A
EPS(NY)0.04
Fwd EY1.06%
FCF(TTM)-0.39
FCFYN/A
OCF(TTM)-0.39
OCFYN/A
SpS1.27
BVpS-1.89
TBVpS-1.89
PEG (NY)N/A
PEG (5Y)N/A
Graham NumberN/A
Profitability
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| ROA | -29.07% | ||
| ROE | N/A | ||
| ROCE | N/A | ||
| ROIC | N/A | ||
| ROICexc | N/A | ||
| ROICexgc | N/A | ||
| OM | N/A | ||
| PM (TTM) | N/A | ||
| GM | 58.2% | ||
| FCFM | N/A |
ROA(3y)-70.33%
ROA(5y)-64.43%
ROE(3y)N/A
ROE(5y)N/A
ROIC(3y)N/A
ROIC(5y)N/A
ROICexc(3y)N/A
ROICexc(5y)N/A
ROICexgc(3y)N/A
ROICexgc(5y)N/A
ROCE(3y)N/A
ROCE(5y)N/A
ROICexgc growth 3YN/A
ROICexgc growth 5YN/A
ROICexc growth 3YN/A
ROICexc growth 5YN/A
OM growth 3YN/A
OM growth 5YN/A
PM growth 3YN/A
PM growth 5YN/A
GM growth 3Y-1.04%
GM growth 5YN/A
F-Score1
Asset Turnover0.83
Health
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| Debt/Equity | N/A | ||
| Debt/FCF | N/A | ||
| Debt/EBITDA | N/A | ||
| Cap/Depr | 0% | ||
| Cap/Sales | 0% | ||
| Interest Coverage | N/A | ||
| Cash Conversion | N/A | ||
| Profit Quality | N/A | ||
| Current Ratio | 1 | ||
| Quick Ratio | 0.7 | ||
| Altman-Z | -5.26 |
F-Score1
WACC8.93%
ROIC/WACCN/A
Cap/Depr(3y)N/A
Cap/Depr(5y)N/A
Cap/Sales(3y)N/A
Cap/Sales(5y)N/A
Profit Quality(3y)N/A
Profit Quality(5y)N/A
High Growth Momentum
Growth
EPS 1Y (TTM)21.87%
EPS 3YN/A
EPS 5YN/A
EPS Q2Q%-6.67%
EPS Next Y68.18%
EPS Next 2Y46.89%
EPS Next 3Y42.98%
EPS Next 5Y65.47%
Revenue 1Y (TTM)2.83%
Revenue growth 3Y61.84%
Revenue growth 5Y17.5%
Sales Q2Q%69.1%
Revenue Next Year26.51%
Revenue Next 2Y8.91%
Revenue Next 3Y9.52%
Revenue Next 5Y29.21%
EBIT growth 1Y-278.55%
EBIT growth 3YN/A
EBIT growth 5YN/A
EBIT Next Year-93.68%
EBIT Next 3Y10.22%
EBIT Next 5Y48.03%
FCF growth 1Y33.79%
FCF growth 3YN/A
FCF growth 5YN/A
OCF growth 1Y33.79%
OCF growth 3YN/A
OCF growth 5YN/A
ESPERION THERAPEUTICS INC / ESPR FAQ
What is the ChartMill fundamental rating of ESPERION THERAPEUTICS INC (ESPR) stock?
ChartMill assigns a fundamental rating of 2 / 10 to ESPR.
What is the valuation status for ESPR stock?
ChartMill assigns a valuation rating of 2 / 10 to ESPERION THERAPEUTICS INC (ESPR). This can be considered as Overvalued.
Can you provide the profitability details for ESPERION THERAPEUTICS INC?
ESPERION THERAPEUTICS INC (ESPR) has a profitability rating of 1 / 10.
Can you provide the financial health for ESPR stock?
The financial health rating of ESPERION THERAPEUTICS INC (ESPR) is 1 / 10.
What is the expected EPS growth for ESPERION THERAPEUTICS INC (ESPR) stock?
The Earnings per Share (EPS) of ESPERION THERAPEUTICS INC (ESPR) is expected to grow by 68.18% in the next year.